RAS-mutant leukaemia stem cells drive clinical resistance to venetoclax.

doi:10.1038/s41586-024-08137-x

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

RAS-mutant leukaemia stem cells drive clinical resistance to venetoclax.

Nature - 1 Dec 2024

Sango Junya, Carcamo Saul, Sirenko Maria, Maiti Abhishek, Mansour Hager, Ulukaya Gulay, Tomalin Lewis E, Cruz-Rodriguez Nataly, Wang Tiansu, Olszewska Malgorzata, Olivier Emmanuel, Jaud Manon, Nadorp Bettina, Kroger Benjamin, Hu Feng, Silverman Lewis, Chung Stephen S, Wagenblast Elvin, Chaligne Ronan, Eisfeld Ann-Kathrin, Demircioglu Deniz, Landau Dan A, Lito Piro, Papaemmanuil Elli, DiNardo Courtney D, Hasson Dan, Konopleva Marina, Papapetrou Eirini P

Abstract excerpt

Cancer driver mutations often show distinct temporal acquisition patterns, but the biological basis for this, if any, remains unknown. RAS mutations occur invariably late in the course of acute myeloid leukaemia, upon progression or relapsed/refractory disease1-6. Here, by using human leukaemogenesis models, we first show that RAS mutations are obligatory late events that need to succeed earlier cooperating...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bridged Bicyclo Compounds, Heterocyclic

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Cell Lineage

Share to Clone Cells

Share to Granulocytes

Share to Monocytes

Share to Neoplastic Stem Cells

Share to Proto-Oncogene Proteins c-bcl-2

Share to Sulfonamides

Source

Open in PubMed Open full text

Identifiers

PMID: 39478230
DOI: 10.1038/s41586-024-08137-x
PMCID: PMC11618090

Genes

BCL2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 9 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

RAS-mutant leukaemia stem cells drive clinical resistance to venetoclax.PMID 39478230Read ↗

Leukemic stem cells and therapy resistance in acute myeloid leukemiaSemantic proximity Read ↗

RAS pathway activation drives clonal selection and monocytic differentiation in FLT3 and BCL2 inhibitor resistanceSemantic proximity Read ↗

A novel type of monocytic leukemia stem cell revealed by the clinical use of venetoclax-based therapySemantic proximity Read ↗

A Novel Type of Monocytic Leukemia Stem Cell Revealed by the Clinical Use of Venetoclax-Based TherapySemantic proximity Read ↗

Monocytic Subclones Confer Resistance to Venetoclax-Based Therapy in Patients with Acute Myeloid LeukemiaSemantic proximity Read ↗

Dysregulated haematopoietic stem cell behaviour in myeloid leukaemogenesis.Semantic proximity Read ↗

Hematopoietic Stem Cells Undergo Differentiation State Reprogramming to Overcome Venetoclax Sensitivity in Patients with Myelodysplastic SyndromesSemantic proximity Read ↗

A Step-wise, Deterministic and Fatal Mouse Model of Myeloid Neoplasm with Spontaneous Acquisition of Patient-relevant RTK–RAS MutationsSemantic proximity Read ↗

Dynamic evolution of venetoclax resistance in acute myeloid leukemia unveiled by longitudinal single-cell RNA-seqSemantic proximity Read ↗

ASXL1 mutations are associated with distinct epigenomic alterations that lead to sensitivity to venetoclax and azacytidine.Semantic proximity Read ↗

PU.1 inhibition sensitizes stem-monocytic AML to BCL2 blockadeSemantic proximity Read ↗

The evolution of leukaemia from pre-leukaemic and leukaemic stem cells.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.